CN106905216A - A kind of proton pump inhibitor medical compounds and preparation method thereof - Google Patents
A kind of proton pump inhibitor medical compounds and preparation method thereof Download PDFInfo
- Publication number
- CN106905216A CN106905216A CN201710256702.XA CN201710256702A CN106905216A CN 106905216 A CN106905216 A CN 106905216A CN 201710256702 A CN201710256702 A CN 201710256702A CN 106905216 A CN106905216 A CN 106905216A
- Authority
- CN
- China
- Prior art keywords
- preparation
- vonoprazan fumarate
- dichloromethane
- proton pump
- pump inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 229940126409 proton pump inhibitor Drugs 0.000 title claims abstract description 17
- 239000000612 proton pump inhibitor Substances 0.000 title claims abstract description 17
- 229950003825 vonoprazan Drugs 0.000 claims abstract description 94
- ROGSHYHKHPCCJW-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine Chemical compound OC(=O)\C=C\C(O)=O.C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F ROGSHYHKHPCCJW-WLHGVMLRSA-N 0.000 claims abstract description 93
- 239000000843 powder Substances 0.000 claims abstract description 22
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 105
- 239000013078 crystal Substances 0.000 claims description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 238000002425 crystallisation Methods 0.000 claims description 42
- 230000008025 crystallization Effects 0.000 claims description 42
- 238000001816 cooling Methods 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 238000000967 suction filtration Methods 0.000 claims description 20
- 239000011259 mixed solution Substances 0.000 claims description 19
- 239000012043 crude product Substances 0.000 claims description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N butenedioic acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- 229910017488 Cu K Inorganic materials 0.000 claims description 9
- 229910017541 Cu-K Inorganic materials 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000000384 rearing effect Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000005259 measurement Methods 0.000 abstract description 11
- 230000005260 alpha ray Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 238000004090 dissolution Methods 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 description 35
- 238000005755 formation reaction Methods 0.000 description 35
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 21
- 239000013558 reference substance Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000001530 fumaric acid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 206010013786 Dry skin Diseases 0.000 description 8
- 150000004684 trihydrates Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241001585714 Nola Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004455 differential thermal analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- -1 pyridin-3-yl sulfonyl Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- RAQPZQAQMHUKTB-TYYBGVCCSA-N (e)-but-2-enedioic acid;methanol Chemical compound OC.OC(=O)\C=C\C(O)=O RAQPZQAQMHUKTB-TYYBGVCCSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000007980 azole derivatives Chemical group 0.000 description 1
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004457 water analysis Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to pharmaceutical technology field, a kind of proton pump inhibitor medical compounds and preparation method thereof is disclosed, specifically, the invention discloses a kind of Vonoprazan fumarate trihydrate and preparation method thereof.The Vonoprazan fumarate trihydrate purity that the present invention is provided is high, good stability, the X ray powder diffractions that it is represented with the 2 θ ± 0.2 ° angles of diffraction are at 2.314 °, 3.517 °, 5.319 °, 7.213 °, 10.362 °, 14.511 °, 20.298 °, 25.277 °, 29.404 °, 32.228 °, 34.447 °, characteristic diffraction peak is shown at 35.552 ° and 36.394 °, the X ray powder diffractograms obtained using Cu K alpha ray measurements are as shown in Figure 1, it is entirely different with prior art, surprisingly find that the Vonoprazan fumarate trihydrate dissolubility that the present invention is obtained is significantly improved through experiment.The invention also discloses the preparation method of Vonoprazan fumarate trihydrate, the preparation method is simple to operation, and reaction condition is gentle, is adapted to large-scale production.The composition tablet dissolution rate and stability that Vonoprazan fumarate trihydrate of the invention is made are significantly improved, and are especially suitable for clinical practice.
Description
Technical field
The invention belongs to pharmaceutical technology field, it is related to a kind of proton pump inhibitor medical compounds and preparation method thereof, has
Body is related to a kind of Vonoprazan fumarate trihydrate and preparation method thereof.
Background technology
Vonoprazan fumarate, chemical entitled 1- [5- (2- fluorophenyls) -1- (pyridin-3-yl sulfonyl) -1H- pyrroles -3-
Base]-N- methyl methylamine fumarates, its molecular formula is：C17H16FN3O2S·C4H4O4, molecular weight：461.46, chemical constitution is such as
Shown in Formulas I.Vonoprazan fumarate is a kind of new proton pump inhibitor, can be used as acid secretion inhibitors, neoplastic disease or from
The medicine of body immunity disease.Omeprazole etc. as proton pump inhibitor can effective gastric acid secretion inhibiting, but in acidity
Under the conditions of unstability and because metabolism enzyme polymorphism and the effect that causes of drug interaction are disperseed, Vonoprazan fumarate
Excellent in stability, more excellent therapeutic effect is shown with to peptic ulcer, reflux esophagitis etc. in acid condition.
One different crystal forms of bulk drug can have different chemically and physically characteristics, including fusing point, chemical reactivity, table
See solubility, optically and mechanically rate of dissolution, property, vapour pressure and density.These characteristics can directly affect bulk drug and system
The treatment and/or production of agent, and stability, solubility and the bioavilability of preparation can be influenceed.When compound has polycrystalline
During type, because specific polymorph has specific macroscopic property and stability, therefore during preparation, understand
The crystal formation of the compound applied in each formulation is important, to ensure the pharmaceutical activity chemical combination of process application same modality
Thing.Therefore, it is that the known mixture of single crystal formation or some crystal formations is necessary to keep pharmaceutical active compounds.
The A of patent CN 105315258 disclose Vonoprazan fumarate new crystal formation A, B and suitable industrialized production
Preparation method, the present invention prepares crystal formation preparation process is simple, and good stability meets medicinal requirements.Crystal formation A its preparation methods are：
Vonoprazan fumarate free alkali is dissolved in ethyl acetate, fumaric acid methanol solution is added, reaction is stirred at room temperature, filtered,
Obtain Vonoprazan fumarate A crystal formations after filter cake drying, crystal formation A is 15.290,20.403,20.704,21.572,25.182,
There is characteristic diffraction peak at 25.559, differential scanning calorimetric collection of illustrative plates has absworption peak at 204.8 DEG C.Crystal formation B its preparation methods are：By richness
Horse acid Wo Nuolazan A crystal formations are dissolved in the ketone aqueous solution of the aqueous solution of the alkylol of C1~C4 or below C4, heating stirring
Dissolving, stirring lets cool；Filtering, Vonoprazan fumarate B crystal form is obtained after filter cake drying, crystal formation B is 12.253,13.559,
15.259th, there is characteristic diffraction peak at 16.889,17.422,20.399,20.764,22.478,25.198,28.077.Differential thermal is swept
Retouch calorimetric collection of illustrative plates has absworption peak at 209.0 DEG C.Two kinds of crystal formations are anhydrous compound after testing.
CN 106478597A disclose a kind of Vonoprazan fumarate monocrystalline and its production and use, and the present invention is rich
Horse acid Wo Nuolazan is easy to be separated with other impurities, and the Vonoprazan fumarate single crystal forms for obtaining are good, and HPLC purity can be high
Up to more than 99.5%, and the reappearance of the method is very good.Additionally, being irrigated using the fumaric acid that the method for the present invention is prepared
Nola praises monocrystalline, it is easy to the absolute structure of product is determined by the X-ray diffraction analysis of monocrystalline, and then, using when ensure that
The accuracy of the medicine containing Vonoprazan fumarate monocrystalline.The preparation method of this monocrystalline is：To Vonoprazan fumarate crude product
Middle addition recrystallisation solvent first alcohol and water (0.25-4:1, preferably 1:1)；And under predetermined temperature (20-30 degrees Celsius), slowly
Volatilization recrystallisation solvent, and culture 5-10 days is carried out, to obtain crystalline product, the crystalline product constitutes the fertile promise of the fumaric acid
Monocrystalline is praised in drawing.Monocrystalline of the present invention in θ=11.4 of the angle of diffraction 2,12.3,13.5,15.1,15.3,16.9,18.6,20.4,20.7,
There is characteristic peak at 22.4 and 25.1.It is detected as anhydrous compound.
The A of CN 106317020 disclose a kind of Vonoprazan fumarate crystal formation α and preparation method thereof, and the crystal form purity is high,
And with good chemical stability and stability of crystal form, it is easy to prepare with scale, simple to operate, low cost, with wide
Application prospect.The preparation method of crystal formation α is：Will Vonoprazan fumarate crude product add glycol monoethyl ether in, heating 60 DEG C~
Backflow dissolving, is subsequently adding purified water, reaction is stirred at room temperature 1~2 hour, filters, and purifies water washing filter cake, dries, and obtains richness
Horse acid Wo Nuolazan crystal formations α.Determined through differential scanning calorimetric analysis (DSC), Vonoprazan fumarate crystal formation α of the invention, with 2
The X-ray powder diffraction (X-RPD) that θ angles are represented at 8.6 ± 0.2 °, 10.2 ± 0.2 °, 12.7 ± 0.2 °, 17.4 ± 0.2 °,
18.1 ± 0.2 °, 19.6 ± 0.2 °, 20.3 ± 0.2 °, 23.2 ± 0.2 °, 24.5 ± 0.2 °, there is diffraction maximum at 27.8 ± 0.2 °；
There is endothermic peak in the range of 166~204 DEG C in its DSC collection of illustrative plates；Preferably, the peak value of the endothermic peak of its DSC collection of illustrative plates appears in 194
At ± 2 DEG C.It is detected as anhydrous compound.
CN106478601A discloses a kind of Vonoprazan fumarate novel crystal forms, its preparation method with ethyl acetate, methyl alcohol,
Purified water is mixed crystallization solvent, obtains the new crystal formation of Vonoprazan fumarate.In its powder x-ray diffraction collection of illustrative plates, spreading out
The θ of firing angle 2 is have characteristic peak at 12.18 ± 0.5,13.43 ± 0.5,22.35 ± 0.5,37.06 ± 0.5,38.25 ± 0.5.This hair
Bright described novel crystal forms have good stability, and can be prevented effectively from the increase of impurity of the drug, reduce the high cost that storage brings, to produce
The security of product and ensure that clinical efficacy brings effective guarantee.It is detected as anhydrous compound.
The A of CN 104327051 disclose a kind of crystal form of the fumarate of azole derivatives, crystal form A purity
Height, good stability is adapted to preparation technical process and long term storage, also has superiority in industrial production.Its preparation method is：
1) by 1- [5- (2- fluorophenyls) -1- (pyridin-3-yl sulfonyl) -1H- pyrroles -3 base]-N- methyl methylamine list fumarates, or
Person adds 1- [5- (2- fluorophenyls) -1- (pyridin-3-yl sulfonyl) -1H- pyrroles -3 base]-N- methyl methylamines and fumaric acid respectively
In appropriate organic solvent, cooling, crystallization, the organic solvent are selected from alcohols, ketone of the carbon number less than or equal to 3 for heat of solution
Any one or a few mixed solvent of class, esters；Or their mixed solvents with water；Described organic solvent may be selected from
Methyl alcohol, ethanol, isopropanol, isobutanol, tert-pentyl alcohol, acetone, butanone, ethyl acetate, isopropyl acetate, tetrahydrofuran, 2- methyl
Tetrahydrofuran, isopropyl ether, methyl tertiary butyl ether(MTBE), methylcyclopentyl ether, acetonitrile, N,N-dimethylformamide, N, N- dimethyl second
Acid amides.2) filtering for crystallizing and wash, dry.Wherein about 5.1 (17.3), 10.1 (8.7), 11.4 (7.7), 11.5 (7.6),
12.2 (7.3), 13.4 (6.6), 13.9 (6.4), 15.2 (5.8), 16.1 (5.5), 16.6 (5.3), 16.9 (5.3) 17.3
(5.1), 17.8 (5.0), 18.5 (4.8), 19.1 (4.7), 20.0 (4.4), 20.3 (4.4), 20.6 (4.3), 21.0 (4.2),
21.5 (4.1), 22.4 (4.0), 23.0 (3.9), 23.5 (3.8), 24.3 (3.7), 25.1 (3.5), 25.5 (3.5) 26.0
(3.4) there is feature at, 26.7 (3.3), 27.6 (3.2), 27.9 (3.2), 28.8 (3.1), 29.1 (3.1), and 29.9 (3.0) places
Peak.Its fusing point is about 203 DEG C.It is detected as anhydrous compound.
, in crystallization, if using different solvent and process conditions, its molecule is in each crystal formation for Vonoprazan fumarate
The number of permutations of structure cell and position and latticed form are different, form different crystal structures, Vonoprazan fumarate polymorphic
Change can change its property, quality and drug effect.Therefore, the stable crystalline of Vonoprazan fumarate, should for further research
The physicochemical properties of compound, study its drug regimen and clinical practice, and tool is of great significance.
Vonoprazan fumarate belongs to insoluble drug, typically applies in solid form in the formulation, the biology of its preparation
Availability quality directly affects its curative effect, and it is more sensitive to illumination, therefore research to its crystal formation has highly important meaning
Justice.In addition, impurity present in medicine influences larger thus appropriate impurity-removing method very necessary the quality of product.Due to
Troublesome impurity is more in Vonoprazan fumarate, and prior art does not provide efficient Vonoprazan fumarate purification process,
It is difficult to take into account yield and purity.The special physicochemical property of Vonoprazan fumarate brings greatly tired to the preparation of hydrate
It is difficult.The present invention has carried out substantial amounts of experiment to existing document technology and has found that obtained Vonoprazan fumarate is equal in the prior art
It is anhydrous compound, it be present, and dissolubility is poor, purity is low, the people's drug safety problem having a strong impact on.
The present invention, using new method for crystallising, has not only obtained a kind of new fumaric acid and has irrigated by substantial amounts of experimental study
Nola praises crystal formation and after measured containing the water of three molecules, the Vonoprazan fumarate trihydrate purity that the present invention is provided is high,
Good stability, surprisingly finds that the Vonoprazan fumarate trihydrate dissolubility that the present invention is obtained is significantly improved through experiment.This
Invention also discloses the preparation method of Vonoprazan fumarate trihydrate, and the preparation method is simple to operation, reaction condition temperature
With suitable large-scale production.Composition tablet dissolution rate and stabilization that Vonoprazan fumarate trihydrate of the invention is made
Property is significantly improved, and is especially suitable for clinical practice.
The content of the invention
The present invention is intended to provide a kind of Vonoprazan fumarate trihydrate and preparation method thereof, technology to be solved is asked
Topic is the dissolubility and purity for improving Vonoprazan fumarate in water, so as to improve the dissolution rate and biological utilisation of its preparation
Degree, to overcome prior art defect.
In order to realize the purpose of the present invention, the technical scheme for using for：
A kind of proton pump inhibitor medical compounds, the compound is Vonoprazan fumarate trihydrate, its molecular formula
For：C17H16FN3O2S·C4H4O4·3H2O, structural formula is following (Formula II), its X-ray powder represented with the 2 θ ± 0.2 ° angles of diffraction
Last diffracting spectrum 2.314 °, 3.517 °, 5.319 °, 7.213 °, 10.362 °, 14.511 °, 20.298 °, 25.277 °,
Characteristic diffraction peak is shown at 29.404 °, 32.228 °, 34.447 °, 35.552 ° and 36.394 °.
The Vonoprazan fumarate trihydrate that the present invention is provided is spread out using the X-ray powder that Cu-K alpha ray measurements are obtained
Penetrate figure as shown in Figure 1.
Present invention also offers a kind of preparation method of Vonoprazan fumarate trihydrate, concretely comprise the following steps：
(1) Vonoprazan fumarate crude product is taken, the mixed solution of dichloromethane/ethanol/water is added, heating stirring dissolves,
Activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise dichloromethane, crystallization of lowering the temperature；
(3) insulated and stirred is complete to crystallization, growing the grain, suction filtration, and washing is dried, and obtains white crystalline powder.
Preferably, in the dichloromethane described in step (1)/ethanol/water mixed solution, the body of dichloromethane, ethanol and water
Product is than being dichloromethane:Ethanol:Water=10:10:1~2；Step (1) the Vonoprazan fumarate crude product and mixed solution
Mass volume ratio is 1g:8ml~10ml；Mixing speed described in step (1) is 20-40 revs/min.
It is further preferred that in dichloromethane/ethanol/water mixed solution described in step (1), dichloromethane, ethanol with
The volume ratio of water is dichloromethane:Ethanol:Water=10:10:1.5；Step (1) the Vonoprazan fumarate crude product with mix molten
The mass volume ratio of liquid is 1g:9ml；Mixing speed described in step (1) is 30 revs/min.
Preferably, the volume ratio 0.5~1 of step (2) dichloromethane and step (1) mixed solution:1；Step (2) institute
Rate of addition is stated for 1.0~2.0mL/min, cooling extent be every 10 minutes 1 DEG C~3 DEG C；Step (2) the cooling crystallization is drop
Temperature extremely -10 DEG C~-5 DEG C crystallizations.
It is further preferred that the volume ratio 0.8 of step (2) dichloromethane and step (1) mixed solution:1；Step
(2) rate of addition be 1.5mL/min, cooling extent be every 10 minutes 2 DEG C；Step (2) the cooling crystallization to be cooled to-
7 DEG C of crystallizations.
Preferably, step (3) described rearing crystal time is 1h~3h；Step (3) described drying temperature is 40 DEG C~50 DEG C.
It is further preferred that step (3) described rearing crystal time is 2h；Step (3) described drying temperature is 45 DEG C.
In the present invention, described Vonoprazan fumarate crude product can be that Vonoprazan fumarate to be further purified is consolidated
Body mixture Vonoprazan fumarate crude product can also be marketable material or be prepared by art methods, the crystalline substance of gained
Type result is novel crystal forms of the present invention in error range.
Present invention also offers a kind of pharmaceutical composition containing Vonoprazan fumarate compound of the present invention, the medicine group
Compound is the tablet containing Vonoprazan fumarate trihydrate.
The formation mechenism of crystal is very complicated, and the acquisition of a new crystal also has very big contingency, and sometimes different is molten
Agent, identical crystal structure can be produced under different crystallization conditions.Some specific crystal formations also can not necessarily obtain more added with
The physicochemical property of profit.The properties such as stability, hygroscopicity, dissolubility, bioactivity, the toxicity of medicine can be produced because of the difference of crystal formation
The huge difference of life.
The present invention is dissolved and different solvent crystallizations by substantial amounts of experiment sieving by selecting different solvents, is obtained
Preparation method of the invention, by the control to mixing speed, solvent load, temperature and rearing crystal time, unexpectedly obtains
A kind of Vonoprazan fumarate novel crystal forms, are detected as trihydrate.The Vonoprazan fumarate purity that the present invention is provided is high, steady
It is qualitative good, surprisingly find that the Vonoprazan fumarate trihydrate dissolubility that the present invention is obtained is significantly improved through experiment.This hair
The bright preparation method for also disclosing Vonoprazan fumarate trihydrate, the preparation method is simple to operation, and reaction condition is gentle,
It is adapted to large-scale production.The composition tablet dissolution rate and stability that Vonoprazan fumarate trihydrate of the invention is made are aobvious
Write and improve, be especially suitable for clinical practice.
Research shows, in the X-ray powder diffraction pattern, the diffraction spectrogram obtained by novel crystal forms is for specific crystal formation
Often characteristic, the wherein relative intensity of bands of a spectrum (especially in low angle) may because of crystallization condition, particle diameter and its
The difference of its condition determination and the advantage orientation effect that produces and change.Therefore, the relative intensity of diffraction maximum is to targeted crystalline substance
Type is not characteristic, when judging whether identical with known crystal formation, it should be noted that the relative position at peak rather than
Their relative intensity.Vonoprazan fumarate provided by the present invention crystallizes its X-ray powder diffraction collection and prior art
Relative position with visibly different peak, it is seen that it is a kind of novel crystal forms unlike the prior art, is detected as three hydrations
Thing.
Vonoprazan fumarate trihydrate crystal provided by the present invention confirms to contain 3 crystallizations water, and its proterties is white
Color crystalline powder, the loss that the crystallization water will not occur under the conditions of air drying.And its powder x-ray diffraction collection of illustrative plates with it is existing
Having technology has the relative position at visibly different peak, it is seen that it is a kind of novel crystal forms unlike the prior art.
Studied to explain and illustrate below by the Vonoprazan fumarate trihydrate crystal formation that the present invention is provided
Technical solution of the present invention：
1st, elementary analysis C17H16FN3O2S·C4H4O4·3H2O
Instrument：VarioELcube elemental analysers；Measurement element is C, H, O, N, S；
DIOENXDX-500 type ion chromatographs；Measurement element is F.
Elementary analysis (%) theoretical value：H (5.08), C (48.93), N (8.15), O (27.93), S (6.22), F
(3.69)。
Elementary analysis (%) measured value is：H (5.10), C (48.94), N (8.16), O (27.91), S (6.20), F
(3.69)。
It is consistent substantially with the theoretical value of elementary analysis.
2nd, crystal formation detection
Take the Vonoprazan fumarate crystallization that the present invention is prepared, the X-ray powder obtained using Cu-K alpha ray measurements
Last diffraction pattern as shown in figure 1, its X-ray powder diffraction figure for being represented with 2 θ ± 0.2 angles of diffraction 2.314 °, 3.517 °,
5.319°、7.213°、10.362°、14.511°、20.298°、25.277°、29.404°、32.228°、34.447°、35.552°
With 36.394 ° at show characteristic peak.
3rd, differential thermal analysis and thermogravimetric analysis
Differential thermal and thermogravimetric analysis are carried out to Vonoprazan fumarate crystal prepared by the present invention, as a result as shown in Figure 2；Knot
Fruit shows that this product quickly loses about 3 weight of hydrone at 110 DEG C or so, and without obvious weight change before 100 DEG C,
Confirm that hydrone that it loses is crystalline water molecules, rather than dissociating water molecule；This product has endothermic peak at about 220 DEG C, from side
It is a kind of different crystal formation to demonstrate it.
4th, water analysis
Determined using cassette moisture teller, the water content of Vonoprazan fumarate of the invention is 10.49%, with theory
Value 10.48% is consistent.
5th, purity detecting
Through HPLC purity detectings, the purity of the Vonoprazan fumarate crystallization that the present invention is prepared can reach 99.98~
99.99%.
Compared with prior art, the invention has the advantages that：
(1) Vonoprazan fumarate provided by the present invention is a kind of novel crystal forms different from prior art, is detected as
Trihydrate；The preparation method of Vonoprazan fumarate trihydrate provided by the present invention is simple to operation, reaction condition temperature
With suitable large-scale production.
(2) present invention provide Vonoprazan fumarate trihydrate purity is high, good stability, surprisingly found through experiment
The Vonoprazan fumarate trihydrate dissolubility that the present invention is obtained is significantly improved.Vonoprazan fumarate of the invention three is hydrated
The composition tablet dissolution rate and stability that thing is made are significantly improved, and are especially suitable for clinical practice.
Brief description of the drawings
The present invention is further illustrated below in conjunction with the accompanying drawings：
Fig. 1 is the X-ray powder diffraction collection of Vonoprazan fumarate trihydrate prepared by the embodiment of the present invention 1.
Fig. 2 is the TG-DSC collection of illustrative plates of Vonoprazan fumarate trihydrate prepared by the embodiment of the present invention 1.
Specific embodiment
Technical scheme is described in detail with embodiment below, it will help to technical scheme
Advantage, effect have and further understand, embodiment does not limit protection scope of the present invention, and protection scope of the present invention is by weighing
Profit requires to determine.
Embodiment 1：The preparation of fumaric acid Wo Nuola trihydrates
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:1) mixed
Close solution 1000ml, (30 revs/min) dissolvings of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (1.0mL/min) dichloromethane 1000ml, cooling (cooling
Amplitude be every 10 minutes 1 DEG C) to -5 DEG C of crystallizations；
(3) insulated and stirred is complete to crystallization, and 1h growing the grains, suction filtration, washing, 40 DEG C of dryings obtain white crystalline powder.
Obtained white crystalline powder is shown in Fig. 1 using the X-ray powder diffraction spectrogram that Cu-K alpha ray measurements are obtained.
Embodiment 2：The preparation of fumaric acid Wo Nuola trihydrates
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:2) mixed
Close solution 800ml, (40 revs/min) dissolvings of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (1.5mL/min) dichloromethane 400ml, cooling (cooling width
Degree be every 10 minutes 3 DEG C) to -10 DEG C of crystallizations；
(3) insulated and stirred is complete to crystallization, and 2h growing the grains, suction filtration, washing, 45 DEG C of dryings obtain white crystalline powder.
X-ray powder diffraction spectrogram and implementation that obtained white crystalline powder is obtained using Cu-K alpha ray measurements
Example 1 is similar.
Embodiment 3：The preparation of fumaric acid Wo Nuola trihydrates
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:1.5)
Mixed solution 900ml, (20 revs/min) dissolvings of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (2.0mL/min) dichloromethane 720ml, cooling (cooling width
Degree be every 10 minutes 2 DEG C) to -8 DEG C of crystallizations；
(3) insulated and stirred is complete to crystallization, and 3h growing the grains, suction filtration, washing, 50 DEG C of dryings obtain white crystalline powder.
X-ray powder diffraction spectrogram and implementation that obtained white crystalline powder is obtained using Cu-K alpha ray measurements
Example 1 is similar.
Embodiment 4：The preparation of fumaric acid Wo Nuola trihydrates
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:2) mixed
Close solution 800ml, (40 revs/min) dissolvings of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (1.5mL/min) dichloromethane 800ml, cooling (cooling width
Degree be every 10 minutes 3 DEG C) to -5 DEG C of crystallizations；
(3) insulated and stirred is complete to crystallization, and 3h growing the grains, suction filtration, washing, 50 DEG C of dryings obtain white crystalline powder.
X-ray powder diffraction spectrogram and implementation that obtained white crystalline powder is obtained using Cu-K alpha ray measurements
Example 1 is similar.
Embodiment 5：The preparation of fumaric acid Wo Nuola trihydrates
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:1) mixed
Close solution 900ml, (30 revs/min) dissolvings of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (2.0mL/min) dichloromethane 450ml, cooling (cooling width
Degree be every 10 minutes 2 DEG C) to -8 DEG C of crystallizations；
(3) insulated and stirred is complete to crystallization, and 2h growing the grains, suction filtration, washing, 45 DEG C of dryings obtain white crystalline powder.
X-ray powder diffraction spectrogram and implementation that obtained white crystalline powder is obtained using Cu-K alpha ray measurements
Example 1 is similar.
Embodiment 6：The preparation of fumaric acid Wo Nuola trihydrates
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:1.5)
Mixed solution 1000ml, (20 revs/min) dissolvings of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (1.0mL/min) dichloromethane 800ml, cooling (cooling width
Degree be every 10 minutes 3 DEG C) to -5 DEG C of crystallizations；
(3) insulated and stirred is complete to crystallization, and 3h growing the grains, suction filtration, washing, 40 DEG C of dryings obtain white crystalline powder.
X-ray powder diffraction spectrogram and implementation that obtained white crystalline powder is obtained using Cu-K alpha ray measurements
Example 1 is similar.
The present invention is further illustrated below by experimental example：
Experimental example 1：Solubility test
Trial target：Sample prepared by embodiment of the present invention 1-6；
Reference substance 1：With reference to Vonoprazan fumarate crystal form A prepared by 104327051 A embodiments of patent CN 1.
Reference substance 2：With reference to Vonoprazan fumarate crystal formation A prepared by 105315258 A embodiments of patent CN 1.
Reference substance 3：With reference to Vonoprazan fumarate crystal formation B prepared by 105315258 A embodiments of patent CN 2.
Reference substance 4：With reference to Vonoprazan fumarate crystal formation α prepared by 106317020 A embodiments of patent CN 1.
Reference substance 5：With reference to Vonoprazan fumarate monocrystalline prepared by patent CN 106478597A embodiments 2.
Reference substance 6：With reference to Vonoprazan fumarate crystal formation prepared by patent CN106478601A embodiments.
Reference substance 7：With reference to Vonoprazan fumarate prepared by 105085484 A embodiments of patent CN 1.
Reference substance 8：With reference to Vonoprazan fumarate crystal prepared by 105130955 A embodiments of patent CN one.
Reference substance 9：With reference to Vonoprazan fumarate crystal prepared by 105294653 A embodiments of patent CN 13.
Reference substance 10：With reference to Vonoprazan fumarate crystal prepared by patent CN106366071A embodiments 10.
Reference substance 11：With reference to Vonoprazan fumarate crystal prepared by 104860926 A embodiments of patent CN 1.
Reference substance 12：With reference to Vonoprazan fumarate crystal prepared by patent 101300229A embodiments 8.
Its dissolubility, method are determined with reference to Chinese Pharmacopoeia two notes on the use of version in 2015：Take this product appropriate, be separately added into water,
Every strength shaking in 5 minutes 30 seconds, the dissolving situation in 30 minutes is observed, obtained final product, the results are shown in Table 1.
The crystal formation of the invention of table 1 and reference substance the dissolubility test result in water
The aqueous sample that above-described embodiment 1-6 is dissolved is stirred 72 hours in 25 DEG C of constant temperature, samples 5ml.Sample is passed through
0.45 μm of filtering with microporous membrane, discards just filtrate, takes the μ L of subsequent filtrate 20 and determines solubility (mg/ml) in medicament contg as water.
The results are shown in Table 2：
Solubility contrast of the crystal formation of the present invention of table 2 with prior art crystal formation in water
As can be seen from the above table, at 25 DEG C, the solubility in water of Vonoprazan fumarate novel crystal forms of the present invention with it is existing
There is technology to compare, be significantly increased, achieve unexpected technique effect.
Experimental example 2：Solvent screening is tested
Operated using preparation method of the invention, it is specific as follows：
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add solvent orange 2 A/water:10:1~2 or 20:1-2 or
10:Mixed solution 800ml-1000ml 1-2), (20-40 revs/min) dissolving of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise (1.0~2.0mL/min) solvent B (solvent B and step (1)
The volume ratio 0.5~1 of mixed solution:1), cooling (cooling extent be every 10 minutes 1 DEG C~3 DEG C) is to -10 DEG C~-5 DEG C crystallizations；
(3) insulated and stirred is complete to crystallization, and 1h~3h growing the grains, suction filtration, washing, 40 DEG C~50 DEG C dryings obtain white crystals
Property powder.
The solvent screening experimental result of table 3
Experimental example 3：Crystallization trial conditional filtering
(1) Vonoprazan fumarate crude product 100g is taken, (volume ratio is 10 to add dichloromethane/ethanol/water:10:1~2)
Mixed solution 800ml-1000ml, the dissolving of (20-40 revs/min) of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to room temperature, be slowly added dropwise (1.0~2.0mL/min) dichloromethane (dichloromethane with
The volume ratio 0.5~1 of step (1) mixed solution:1), cooling (cooling extent be every 10 minutes 1 DEG C~3 DEG C) is to -10 DEG C~-5
DEG C crystallization；
(3) insulated and stirred is complete to crystallization, and 1h~3h growing the grains, suction filtration, washing, 40 DEG C~50 DEG C dryings obtain white crystals
Property powder.
Table 4-1 crystallization trial conditional filtering results
Table 4-2 crystallization trial conditional filtering results
Experimental example 4：Stability test
Experimental example investigates the stabilization of the Vonoprazan fumarate trihydrate crystal that the present invention is provided by accelerated test
Property.
Sample prepared by Example 1-3, places 6 months under conditions of 40 ± 2 DEG C of temperature, relative humidity 75 ± 5%,
Proterties, relevant material, content is measured by sampling respectively at 0,1,2,3,6 the end of month, 5 are the results are shown in Table.
Table 5：Accelerated test result (40 ± 2 DEG C of temperature, relative humidity 75 ± 5%)
As seen from Table 5, Vonoprazan fumarate crystallization of the present invention is in 40 ± 2 DEG C of temperature, the condition of relative humidity 75 ± 5%
Lower to place 6 months, relevant content of material does not have significantly raised, and each index has no significant change, and illustrates this product good stability, while
In Acceleration study, water content is stable (trihyarol), and it is the crystallization water that the water in the compound is demonstrated from another point of view for this product
It is not absorption water.
Claims (10)
1. a kind of proton pump inhibitor medical compounds, it is characterised in that described compound is the water of Vonoprazan fumarate three
Compound, its molecular formula is：C17H16FN3O2S·C4H4O4·3H2O, it is spread out with the X-ray powder that the 2 θ ± 0.2 ° angles of diffraction are represented
Penetrate collection of illustrative plates 2.314 °, 3.517 °, 5.319 °, 7.213 °, 10.362 °, 14.511 °, 20.298 °, 25.277 °, 29.404 °,
Characteristic diffraction peak is shown at 32.228 °, 34.447 °, 35.552 ° and 36.394 °.
2. a kind of proton pump inhibitor medical compounds as claimed in claim 1, it is characterised in that surveyed using Cu-K alpha rays
The X-ray powder diffraction figure for measuring is as shown in Figure 1.
3. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 1 or 2, it is characterised in that including
Following steps：
(1) Vonoprazan fumarate crude product is taken, the mixed solution of dichloromethane/ethanol/water, heating stirring dissolving, activity is added
Carbon decoloring, suction filtration；
(2) step (1) filtrate is down to room temperature, is slowly added dropwise dichloromethane, crystallization of lowering the temperature；
(3) insulated and stirred is complete to crystallization, growing the grain, suction filtration, and washing is dried, and obtains white crystalline powder.
4. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 3, it is characterised in that step
(1) in the dichloromethane/ethanol/water mixed solution described in, the volume ratio of dichloromethane, ethanol and water is dichloromethane:Ethanol:
Water=10:10:1~2；Step (1) the Vonoprazan fumarate crude product is 1g with the mass volume ratio of mixed solution:8ml~
10ml；Mixing speed described in step (1) is 20-40 revs/min.
5. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 4, it is characterised in that step
(1) in the dichloromethane/ethanol/water mixed solution described in, the volume ratio of dichloromethane, ethanol and water is dichloromethane:Ethanol:
Water=10:10:1.5；Step (1) the Vonoprazan fumarate crude product is 1g with the mass volume ratio of mixed solution:9ml；Step
Suddenly the mixing speed described in (1) is 30 revs/min.
6. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 4, it is characterised in that step
(2) volume ratio 0.5~1 of the dichloromethane and step (1) mixed solution:1；Step (2) described rate of addition be 1.0~
2.0mL/min, cooling extent be every 10 minutes 1 DEG C~3 DEG C；Step (2) the cooling crystallization is to be cooled to -10 DEG C~-5 DEG C analysis
It is brilliant.
7. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 4, it is characterised in that step
(2) volume ratio 0.8 of the dichloromethane and step (1) mixed solution:1；Step (2) described rate of addition is 1.5mL/min,
Cooling extent be every 10 minutes 2 DEG C；Step (2) the cooling crystallization is to be cooled to -7 DEG C of crystallizations.
8. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 4, it is characterised in that step
(3) rearing crystal time is 1h~3h；Step (3) described drying temperature is 40 DEG C~50 DEG C.
9. a kind of preparation method of proton pump inhibitor medical compounds as claimed in claim 8, it is characterised in that step
(3) rearing crystal time is 2h；Step (3) described drying temperature is 45 DEG C.
10. a kind of pharmaceutical composition containing a kind of any described proton pump inhibitor medical compounds of claim 1~2,
Characterized in that, described pharmaceutical composition is the tablet containing Vonoprazan fumarate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710256702.XA CN106905216A (en) | 2017-04-19 | 2017-04-19 | A kind of proton pump inhibitor medical compounds and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710256702.XA CN106905216A (en) | 2017-04-19 | 2017-04-19 | A kind of proton pump inhibitor medical compounds and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106905216A true CN106905216A (en) | 2017-06-30 |
Family
ID=59210786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710256702.XA Pending CN106905216A (en) | 2017-04-19 | 2017-04-19 | A kind of proton pump inhibitor medical compounds and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106905216A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115557876A (en) * | 2022-10-26 | 2023-01-03 | 四川国康药业有限公司 | A 3-aryl ring sulfonyl-1-N-heteropyrrole derivative for treating peptic ulcer, its preparation method and application |
| IT202400004474A1 (en) * | 2024-02-29 | 2025-08-29 | Dipharma Francis S R L | METHOD OF PURIFICATION OF A DRUG USED FOR THE TREATMENT OF GASTRIC ACIDITY |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101300229A (en) * | 2005-08-30 | 2008-11-05 | 武田药品工业株式会社 | 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero)aryl substituted 1-H-pyrrole derivatives as gastric acid secretion inhibitors |
| CN103951652A (en) * | 2014-04-18 | 2014-07-30 | 潍坊博创国际生物医药研究院 | Water soluble salts of organic acid 5-(2-fluorophenyl)-N-methyl-1-(3-pyridyl sulfonyl)-1H-pyrrole-3-methylamine and injection and preparation method thereof |
| CN106478601A (en) * | 2016-09-27 | 2017-03-08 | 海口南陆医药科技股份有限公司 | A kind of Vonoprazan fumarate novel crystal forms and preparation method thereof |
| CN107759568A (en) * | 2016-08-22 | 2018-03-06 | 四川海思科制药有限公司 | Wo Nuolazan salt, crystal formation and its production and use |
-
2017
- 2017-04-19 CN CN201710256702.XA patent/CN106905216A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101300229A (en) * | 2005-08-30 | 2008-11-05 | 武田药品工业株式会社 | 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero)aryl substituted 1-H-pyrrole derivatives as gastric acid secretion inhibitors |
| CN103951652A (en) * | 2014-04-18 | 2014-07-30 | 潍坊博创国际生物医药研究院 | Water soluble salts of organic acid 5-(2-fluorophenyl)-N-methyl-1-(3-pyridyl sulfonyl)-1H-pyrrole-3-methylamine and injection and preparation method thereof |
| CN107759568A (en) * | 2016-08-22 | 2018-03-06 | 四川海思科制药有限公司 | Wo Nuolazan salt, crystal formation and its production and use |
| CN106478601A (en) * | 2016-09-27 | 2017-03-08 | 海口南陆医药科技股份有限公司 | A kind of Vonoprazan fumarate novel crystal forms and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 宋建伟: ""TAK-438水溶性有机酸盐的设计、合成及生物学评价"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115557876A (en) * | 2022-10-26 | 2023-01-03 | 四川国康药业有限公司 | A 3-aryl ring sulfonyl-1-N-heteropyrrole derivative for treating peptic ulcer, its preparation method and application |
| IT202400004474A1 (en) * | 2024-02-29 | 2025-08-29 | Dipharma Francis S R L | METHOD OF PURIFICATION OF A DRUG USED FOR THE TREATMENT OF GASTRIC ACIDITY |
| WO2025181220A1 (en) * | 2024-02-29 | 2025-09-04 | Dipharma Francis S.R.L. | Process of purifying a drug used in the treatment of acid-related disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106892900A (en) | A kind of Vonoprazan fumarate and preparation method thereof | |
| CN102086195B (en) | Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof | |
| WO2023078424A1 (en) | Crystal form of kras mutant inhibitor, preparation method therefor, and use thereof | |
| CN101671314B (en) | A crystal form of febuxostat and its preparation method | |
| CN107428727A (en) | Novel crystal forms of HKI-272 maleate and preparation method thereof | |
| WO2021000687A1 (en) | Preparation method for crystal form of pac-1 | |
| CN106349192B (en) | The eutectic of orlistat and amino acid and include eutectiferous pharmaceutical composition | |
| RU2648990C1 (en) | Lobaplatin crystals, methods of production and applications in pharmaceuticals | |
| CN106905216A (en) | A kind of proton pump inhibitor medical compounds and preparation method thereof | |
| CN106966944B (en) | Vildagliptin crystal form compound and preparation method thereof | |
| CN107163025A (en) | It is a kind of to treat medical compounds of disease of digestive system and preparation method thereof | |
| CN103497178B (en) | Irbesartan and repaglinide co-amorphous substance | |
| CN114105969A (en) | Crystal form of BTRX-335140 and preparation method thereof | |
| CN107739358A (en) | A kind of daidzein anhydrous crystal forms II, preparation method and its medical usage | |
| CN114057643B (en) | Rosemastat eutectic crystal and preparation method thereof | |
| CN102250084A (en) | Dasatinib polymorphic substance as well as preparation method and pharmaceutical composition thereof | |
| CN107011327A (en) | It is a kind of to treat medical compounds of peptic ulcer and preparation method thereof | |
| CN110372576A (en) | A kind of calcium channel blocking drug molecule eutectic and preparation method thereof | |
| CN104447671B (en) | Bellidifolin single crystal as well as preparation method and application thereof | |
| CN115724796A (en) | New crystal form of roxasistat and preparation method thereof | |
| CN106478598B (en) | A kind of Vande Thani hydrate crystal and preparation method thereof | |
| CN106866519B (en) | A kind of roflumilast crystal-form compound and preparation method thereof | |
| CN107056721B (en) | A kind of Parecoxib Sodium crystalline compounds and preparation method thereof | |
| WO2015123801A1 (en) | Preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof | |
| CN105523994B (en) | Methanesulfonic acid Lome Tapai crystal form III |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170630 |
|
| RJ01 | Rejection of invention patent application after publication |